Anti-CGRP Antibodies for Brain-Penetrant CINV Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antiemetic drugs are ineffective in treating chemotherapy-induced nausea and vomiting (CINV) and often lose efficacy over time, and current anti-CGRP monoclonal antibodies cannot cross the blood-brain barrier to modulate central nervous system neurotransmission.
Innovation Solution
Subcutaneous administration of anti-CGRP monoclonal antibodies such as fremanezumab, galcanezumab, and eptinezumab leads to their unexpected accumulation in the brain, effectively reducing nausea and vomiting induced by antitumor chemotherapeutics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If anti-CGRP monoclonal antibodies are administered peripherally, then they can be delivered systemically, but they cannot cross the blood-brain barrier to reach the central nervous system
Solution Approach 1:
The patent utilizes the monoclonal antibody itself as an intermediary that can traverse the blood-brain barrier through receptor-mediated transcytosis, a mechanism where the antibody binds to peripheral type 3 iodothyronine deiodinase (D3) in the brain and is transported across the blood-brain barrier. This resolves the contradiction by finding a natural transport pathway that allows peripheral administration to effectively deliver the antibody to the central nervous system target.
2Adaptability or versatility
If conventional antiemetics are used for CINV, then they treat general nausea and vomiting, but they are ineffective for chemotherapy-induced nausea and vomiting
Solution Approach 1:
The patent applies local quality by targeting the specific CGRP receptor in the area postrema and nucleus tractus solitarius of the brainstem, which are specifically involved in CINV pathways. Rather than using broad-spectrum antiemetics, the invention focuses on the local neuroanatomical and biochemical characteristics of CINV, targeting CGRP signaling in these specific brain regions to achieve effective CINV treatment.
Solution Approach 2:
The patent changes the therapeutic parameter from general neurotransmitter targeting to specific neuropeptide (CGRP) targeting. By monoclonal antibodies that specifically bind and neutralize CGRP, the treatment addresses the specific pathophysiological parameter of CGRP-mediated emesis in CINV, which differs from the mechanisms of general antiemetics.
3Reliability
If specific CINV antiemetics are used, then they target the chemoreceptor trigger zone, but they lose efficacy over treatment cycles
Solution Approach 1:
The patent converts the previously overlooked peripheral administration route into a benefit by demonstrating that peripheral administration of anti-CGRP monoclonal antibodies effectively treats CINV. This approach bypasses the tolerance and efficacy loss issues associated with continuous central acting antiemetics, providing a sustainable long-term treatment solution.
Data Source
AI summary
A method in which anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies are used for direct treatment of nausea and for vomiting, including chemotherapy-induced nausea and vomiting (CINV) induced by multiple triggers. Among them, drugs frequently prompt nausea and vomiting, such as antitumor chemotherapeutics which are among the most emetic drugs and often cause CINV, which in turn can severely compromise efficacy of therapy, as well as patient quality of life. The method uses anti-CGRP monoclonal antibodies to target calcitonin gene related peptide (CGRP), a neuropeptide with pleiotypic effects in the human body, to prevent and counteract CINV.